No Data
Wuhan Hiteck Biological Pharma (300683.SZ): The company has changed its pharmaceutical production license, and the production scope now includes suppositories.
On December 27, GELONGHUI reported that Wuhan Hiteck Biological Pharma (300683.SZ) stated on an investor interaction platform that the company recently obtained a new "Pharmaceutical Production License" issued by the Hubei Provincial Drug Administration, approving the application for the change of the "Pharmaceutical Production License." The new license adds suppository preparations to the range of production, with other content unchanged. Due to the need for the transfer of the suppository preparation approval number, this "Pharmaceutical Production License" adds the production range for Suppository Preparation B. The above changes will not have a significant impact on the company's performance. Investors are urged to invest rationally and pay attention to investment risks.
Wuhan Hiteck Biological Pharma (300683.SZ): Injection of rohitidine hydrochloride acetate and ketoconazole injection is expected to be selected for the national Pharmaceutical centralized procurement.
Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company participated in the national organization of pharmaceutical joint procurement office's tenth...
Wuhan Hiteck Biological Pharma (300683.SZ): The company's products are expected to be selected for the national Pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that on December 12, 2024, the company participated in the 10th batch of national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). According to the "Public Notice of Proposed Winning Results for National Pharmaceutical Centralized Procurement" released by the Joint Procurement Office, the company's products, injection of ropivacaine hydrochloride and injection of theophylline, are proposed to be selected for this centralized procurement. According to the rules of this centralized procurement, the procurement period for each variety nationwide will be from the date of the announced winning results until December 31, 2027. During the procurement period, procurement agreements will be established.
Wuhan Hiteck Biological Pharma (300683.SZ): Plans to distribute a cash dividend of 1.3 yuan for every 10 shares to all shareholders.
On December 10, Geelong Hu announced that Wuhan Hiteck Biological Pharma (300683.SZ) disclosed that the Board of Directors has drafted the profit distribution plan for the first half of 2024 under the premise of adhering to the profit distribution principles and ensuring the normal Operation and long-term development of the company. Based on a total share capital of 130,894,391 shares as of the disclosure date of this announcement, it is proposed to distribute a cash dividend of 1.30 yuan (tax included) for every 10 shares to all Shareholders, totaling a cash dividend distribution of 17,016,270.83 yuan (tax included). This profit distribution does not increase the share capital, nor is there a bonus issue.
Wuhan Hiteck Biological Pharma (300683.SZ): Epinephrine injection included in the national medical insurance catalog.
On November 28th, wuhan hiteck biological pharma (300683.SZ) announced that, according to the "Notice on Issuing the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2024)" [Medical Insurance Development [2024] No. 33] issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security, Epinephrine for Injection by wuhan hiteck biological pharmaceutical co., Ltd. (hereinafter referred to as the 'Company') was included in the 'National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2024)' (hereinafter referred to as the '2024 National Medical Insurance List') for the first time through negotiation. Injection.
Wuhan Hiteck Biological Pharma (300683.SZ) has obtained the pharmaceutical registration certificate for ketamine hydrochloride injection.
On November 6, Guolonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company recently received the 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration for the injection of ketoprofen. Ketoprofen injection is suitable for peripheral arterial disease (intermittent claudication or rest pain), inner ear circulatory disorders, and is a national medical insurance category B variety. Ketoprofen and its metabolites improve blood rheological properties by reducing blood viscosity, increasing blood flow to affected microcirculation in patients with chronic peripheral arterial disease, and enhancing tissue oxygenation. It dose-dependently improves blood rheology and can reduce blood viscosity.